Moneycontrol PRO

Sun Pharma: Traction in select speciality comes as a surprise

Though valuation is still not inexpensive, we see improved trade sentiment for Sun Pharma post results. Sustained traction in speciality will be a key re-rating driver

November 04, 2020 / 11:56 AM IST
Sun Pharma: Traction in select speciality comes as a surprise

Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Highlights - Q2 sales helped by international markets and API performance - Improved margins mainly due to product mix; may not sustain in the medium term - Few specialty products to break even next fiscal - Sustained traction in speciality to be a re-rating driver India’s largest pharma company Sun Pharma (CMP: Rs 485 Market cap: Rs 116,392 crore) posted a better-than-expected set of numbers, driven by speciality products and improved performance in international markets. Other than that, balance sheet improvement and traction in the plaque psoriasis market...

  • PRO Panorama

    Moneycontrol Pro Panorama | Red-hot yield: What can calm the markets’ nerves?

    Jan 19, 2022 / 04:12 PM IST

    In today’s edition of Moneycontrol Pro Panorama: What AGS IPO brings to the table, Unilever’s gambit, Budget Chart of the Day, the cotton trouble and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | Advance GDP data show a K-shaped recovery

    Jan 8, 2022 / 09:21 AM IST

    The biggest takeaway from the advance estimates is the weakness in private consumption. For the second half of FY22, the growth in private consumption is expected to be a mere 1.8%

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers